DK1482938T3 - Farmaceutisk præparat af en PDE4 eller en PDE3/4 inhibitor og en histaminreceptorantagonist - Google Patents

Farmaceutisk præparat af en PDE4 eller en PDE3/4 inhibitor og en histaminreceptorantagonist

Info

Publication number
DK1482938T3
DK1482938T3 DK03708130T DK03708130T DK1482938T3 DK 1482938 T3 DK1482938 T3 DK 1482938T3 DK 03708130 T DK03708130 T DK 03708130T DK 03708130 T DK03708130 T DK 03708130T DK 1482938 T3 DK1482938 T3 DK 1482938T3
Authority
DK
Denmark
Prior art keywords
pde3
pde4
inhibitor
receptor antagonist
pharmaceutical preparation
Prior art date
Application number
DK03708130T
Other languages
Danish (da)
English (en)
Inventor
Rolf Beume
Daniela Bundschuh
Christian Weimar
Stefan-Lutz Wollin
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Application granted granted Critical
Publication of DK1482938T3 publication Critical patent/DK1482938T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK03708130T 2002-03-06 2003-02-25 Farmaceutisk præparat af en PDE4 eller en PDE3/4 inhibitor og en histaminreceptorantagonist DK1482938T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02004987 2002-03-06
PCT/EP2003/001876 WO2003074055A1 (en) 2002-03-06 2003-02-25 Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist

Publications (1)

Publication Number Publication Date
DK1482938T3 true DK1482938T3 (da) 2007-12-03

Family

ID=27771841

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03708130T DK1482938T3 (da) 2002-03-06 2003-02-25 Farmaceutisk præparat af en PDE4 eller en PDE3/4 inhibitor og en histaminreceptorantagonist
DK07112823.5T DK1849468T3 (da) 2002-03-06 2003-02-25 Farmaceutisk sammensætning omfattende roflumilast og levocetirizin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK07112823.5T DK1849468T3 (da) 2002-03-06 2003-02-25 Farmaceutisk sammensætning omfattende roflumilast og levocetirizin

Country Status (31)

Country Link
US (1) US20050112069A1 (enExample)
EP (2) EP1849468B1 (enExample)
JP (1) JP5150034B2 (enExample)
KR (1) KR20040095255A (enExample)
CN (1) CN101257904A (enExample)
AR (1) AR038858A1 (enExample)
AT (1) ATE369134T1 (enExample)
AU (1) AU2003212268B2 (enExample)
BR (1) BR0308220A (enExample)
CA (1) CA2478612C (enExample)
CO (1) CO5611148A2 (enExample)
CY (2) CY1106927T1 (enExample)
DE (1) DE60315426T2 (enExample)
DK (2) DK1482938T3 (enExample)
EA (2) EA010886B1 (enExample)
ES (2) ES2291618T3 (enExample)
HR (1) HRP20040909B1 (enExample)
IL (1) IL163336A (enExample)
IS (2) IS2536B (enExample)
MX (1) MXPA04008460A (enExample)
NO (1) NO335254B1 (enExample)
NZ (1) NZ535611A (enExample)
PL (1) PL211574B1 (enExample)
PT (2) PT1849468E (enExample)
RS (1) RS51018B (enExample)
SG (1) SG160197A1 (enExample)
SI (2) SI1482938T1 (enExample)
TW (1) TWI347845B (enExample)
UA (1) UA80117C2 (enExample)
WO (1) WO2003074055A1 (enExample)
ZA (1) ZA200407104B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067433B2 (en) * 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
EP2091538B1 (en) * 2006-12-20 2010-03-03 Glaxo Group Limited 4-benzyl-1(2h)-phthalazinones as h1 receptor antagonists
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
US20080254029A1 (en) * 2007-04-11 2008-10-16 Alcon Research, Ltd. Use of an Inhibitor of TNFa Plus an Antihistamine to Treat Allergic Rhinitis and Allergic Conjunctivitis
WO2009067597A1 (en) * 2007-11-21 2009-05-28 Decode Genetics Ehf 4- (or 5-) substituted catechol derivatives
KR20090061972A (ko) * 2007-12-12 2009-06-17 한미약품 주식회사 베포타스틴 p-톨루엔술폰산염의 결정형, 이의 제조방법 및이를 포함하는 약학 조성물
KR101852222B1 (ko) 2011-02-07 2018-04-25 에스씨아이팜 에스에이알엘 낭포성 섬유증의 치료를 위한 신규 조성물
KR102226833B1 (ko) * 2013-06-28 2021-03-12 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성이 개선된 복합 과립 제형
JP2017525721A (ja) * 2014-08-26 2017-09-07 ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダFundacion Para La Investigasion Medica Aplicada 認知欠損または認知障害に伴って進行する神経障害のおよび神経変性疾患の処置および予防のための製品
BR112017007194B1 (pt) 2014-10-09 2023-11-07 Guangdong Raynovent Biotech Co., Ltd Compostos de hidroxil purina e uso dos mesmos
CN109956947A (zh) * 2017-12-25 2019-07-02 江苏恒瑞医药股份有限公司 一种cns抑制剂的新晶型、制备方法及用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
HU220041B (hu) * 1993-07-02 2001-10-28 Byk Gulden Lomberg Chemische Fabrik Gmbh. Fluor-alkoxi-helyettesített benzamidszármazékok, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyászati készítmények
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5990147A (en) * 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
BR9804993A (pt) * 1998-11-10 2000-06-06 Panacea Biotec Ltd Composição antialérgica e antiinflamatória
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
EP1244654A1 (en) * 1999-10-25 2002-10-02 ALTANA Pharma AG Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
GB0115181D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use

Also Published As

Publication number Publication date
TW200306855A (en) 2003-12-01
US20050112069A1 (en) 2005-05-26
ZA200407104B (en) 2006-12-27
CA2478612C (en) 2013-12-10
ES2400670T3 (es) 2013-04-11
SG160197A1 (en) 2010-04-29
TWI347845B (en) 2011-09-01
ATE369134T1 (de) 2007-08-15
KR20040095255A (ko) 2004-11-12
UA80117C2 (uk) 2007-08-27
NO335254B1 (no) 2014-10-27
CN101257904A (zh) 2008-09-03
AU2003212268A1 (en) 2003-09-16
PT1849468E (pt) 2013-02-27
IS7438A (is) 2004-09-03
ES2291618T3 (es) 2008-03-01
EP1849468B1 (en) 2012-12-05
EP1482938A1 (en) 2004-12-08
HRP20040909B1 (en) 2012-11-30
EP1849468A3 (en) 2007-11-07
DE60315426T2 (de) 2008-07-03
SI1482938T1 (sl) 2007-12-31
PT1482938E (pt) 2007-11-15
WO2003074055A1 (en) 2003-09-12
EA200401137A1 (ru) 2005-04-28
CY1113894T1 (el) 2016-07-27
IL163336A (en) 2009-02-11
EP1482938B1 (en) 2007-08-08
MXPA04008460A (es) 2004-12-06
NO20044230L (no) 2004-12-06
PL371056A1 (en) 2005-06-13
HK1071308A1 (en) 2005-07-15
SI1849468T1 (sl) 2013-03-29
JP5150034B2 (ja) 2013-02-20
DK1849468T3 (da) 2013-02-04
PL211574B1 (pl) 2012-05-31
AU2003212268B2 (en) 2008-09-11
BR0308220A (pt) 2005-01-04
IS8760A (is) 2008-09-04
DE60315426D1 (de) 2007-09-20
AR038858A1 (es) 2005-01-26
CA2478612A1 (en) 2003-09-12
HRP20040909A2 (en) 2005-08-31
EA200601592A1 (ru) 2006-12-29
CO5611148A2 (es) 2006-02-28
EA007903B1 (ru) 2007-02-27
CY1106927T1 (el) 2012-09-26
JP2005524666A (ja) 2005-08-18
EP1849468A2 (en) 2007-10-31
NZ535611A (en) 2006-03-31
RS51018B (sr) 2010-10-31
RS78004A (sr) 2006-12-15
IS2536B (is) 2009-08-15
EA010886B1 (ru) 2008-12-30

Similar Documents

Publication Publication Date Title
IS8760A (is) Lyfjablanda úr pde4 eða pde3/4 tálma og histamínviðtakamótlyfi
DE60103974D1 (de) Gyrase-inhibitoren und ihre verwendung
NO20040469L (no) Heterocykliske forbindelser samt fremstilling og anvendelse derav
DK1455756T3 (da) Farmaceutisk nanopartikelformig sammensætning af en Tachykinin-receptor-antagonist
DK1122244T3 (da) Uracilforbindelser og anvendelse deraf
DK1411923T3 (da) Farmaceutisk sammensætning af amlodipin og atorvastatin
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
DK1527067T3 (da) 4-Trifluormethylpyrazolylsubstituerede pyridiner og pyrimidiner
DE60234167D1 (de) Bipiperidin-derivate und ihre verwendung als inhibitoren der chemokinrezeptoren
AR028281A1 (es) Derivados de 2-(arilalquilamino) pirimidona y derivados de 2-(heteroaroarilalquilamino) pirimidona
DK1335906T3 (da) Pyrimidinderivater og anvendelse deraf som neuropeptid Y-receptorligander
ITMI20021247A1 (it) Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
DK1106607T3 (da) Uracilforbindelser og anvendelse deraf
NO20031997L (no) CRF-reseptor-antagonist og metoder relatert dertil
PT1448566E (pt) Antagonistas do receptor quimioquina e metodos de utilizacao do mesmo
EP1461450A4 (en) T-BET COMPOSITIONS AND METHOD OF USE THEREOF
NO20033223D0 (no) Histamin-reseptor antagonister
PT1392670E (pt) Derivados substituidos de c-furan-2-il-metilamina e c-tiofen-2-il-metilamina
DE60203934D1 (de) Pharmazeutische kombination von adenosine a-2a und beta-2-adrenergen rezeptoren agonisten
DK1440067T3 (da) N-formyl-derivater af paroxetin
DE60011801D1 (de) Benzoxa- und benzthiazolylsulfamate sowie ihre verwendung als steroid-sulfataseinhibitoren
AU2003248853A8 (en) Detection of drug-resistant human immunodeficiency virus
FR2861103B1 (fr) Dispositif anti-soulevement et de maintien d'elements d'ouvrage d'art
EE200300075A (et) Angiotensiin II antagonistide ja ACE inhibiitorite farmatseutiline kombinatsioon
SE0203540D0 (sv) Use of an inhibilor or antagonist against lissue factor